Experienced in Cavernous Lymphangioma

Chien-liang K. Liu

Heping Fuyou Branch, 
Taipei, TNQ, TW 
Experienced in Cavernous Lymphangioma
Heping Fuyou Branch, 
Taipei, TNQ, TW 
OverviewLocationsClinical Research

Overview

Chien-liang Liu practices in Taipei, Taiwan. Liu is rated as an Experienced expert by MediFind in the treatment of Cavernous Lymphangioma. Their top areas of expertise are Thyroid Cancer, Papillary Thyroid Cancer, Cavernous Lymphangioma, Parathyroidectomy, and Thyroidectomy.

Their clinical research consists of co-authoring 118 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Cavernous Lymphangioma.

Locations

Heping Fuyou Branch, Taipei, TNQ, Taiwan
Other Locations
101 Hsin Ann Road, Hsinchu Science Park, Hsinchu, TNQ 30076, Taiwan
No. 1, Sec. 4, Roosevelt Road, TPQ 10617, Taiwan
92 Chung Shan North Road, TPQ 10449, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3

118 Total Publications

WITHDRAWN: Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function.
WITHDRAWN: Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function.
Journal: Molecular cell
Published: August 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Liu's expertise for a condition
ConditionClose
      View All 22 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile